The path to routine use of genomic biomarkers in the cancer clinic

Genome Research

Volumn 25, Issue 10, 2015, Pages 1508-1513

  Boutros, Paul C ^a,b,c  

^a ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; TUMOR MARKER;

BIOLOGY; CANCER CENTER; CANCER PATIENT; CLINICAL DECISION MAKING; GENE MUTATION; GENOME ANALYSIS; GENOMICS; HIGH THROUGHPUT SEQUENCING; MACHINE LEARNING; MARKER GENE; MASS SCREENING; NEXT GENERATION SEQUENCING; PATIENT CARE; PHARMACOECONOMICS; PRIORITY JOURNAL; REPRODUCIBILITY; REVIEW; SOMATIC MUTATION; ECONOMICS; GENETIC SCREENING; GENETICS; HUMAN; MEDICAL INFORMATION; NEOPLASMS; TRENDS;

BIOMARKERS, TUMOR; GENETIC TESTING; GENOMICS; HEALTH COMMUNICATION; HUMANS; NEOPLASMS; REPRODUCIBILITY OF RESULTS;

EID: 84942862056     PISSN: 10889051     EISSN: 15495469     Source Type: Journal    
DOI: 10.1101/gr.191114.115     Document Type: Review

References (79)

1. Aerts HJ, Velazquez ER, Leijenaar RT, Parmar C, Grossmann P, Cavalho S, Bussink J, Monshouwer R, Haibe-Kains B, Rietveld D, et al. 2014. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun 5: 4006.
2. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, Borresen-Dale AL, et al. 2013a. Signatures of mutational processes in human cancer. Nature 500: 415-421.
3. Alexandrov LB, Nik-Zainal S, Wedge DC, Campbell PJ, Stratton MR. 2013b. Deciphering signatures of mutational processes operative in human cancer. Cell Rep 3: 246-259.
4. Anglesio MS, Bashashati A, Wang YK, Senz J, Ha G, Yang W, Aniba MR, Prentice LM, Farahani H, Li Chang H, et al. 2015. Multifocal endometriotic lesions associated with cancer are clonal and carry a high mutation burden. J Pathol 236: 201-209.
5. Baca SC, Prandi D, Lawrence MS, Mosquera JM, Romanel A, Drier Y, Park K, Kitabayashi N, MacDonald TY, Ghandi M, et al. 2013. Punctuated evolution of prostate cancer genomes. Cell 153: 666-677.
6. Bachtiary B, Boutros PC, Pintilie M, Shi W, Bastianutto C, Li JH, Schwock J, Zhang W, Penn LZ, Jurisica I, et al. 2006. Gene expression profiling in cervical cancer: an exploration of intratumor heterogeneity. Clin Cancer Res 12: 5632-5640.
7. Bashashati A, Ha G, Tone A, Ding J, Prentice LM, Roth A, Rosner J, Shumansky K, Kalloger S, Senz J, et al. 2013. Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling. J Pathol 231: 21-34.
8. Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY, Sboner A, Esgueva R, Pflueger D, Sougnez C, et al. 2011. The genomic complexity of primary human prostate cancer. Nature 470: 214-220.
9. Boutros PC, Lau SK, Pintilie M, Liu N, Shepherd FA, Der SD, Tsao MS, Penn LZ, Jurisica I. 2009. Prognostic gene signatures for non-small-cell lung cancer. Proc Natl Acad Sci 106: 2824-2828.
10. Boutros PC, Ewing AD, Ellrott K, Norman TC, Dang KK, Hu Y, Kellen MR, Suver C, Bare JC, Stein LD, et al. 2014a. Global optimization of somatic variant identification in cancer genomes with a global community challenge. Nat Genet 46: 318-319.
11. Boutros PC, Margolin AA, Stuart JM, Califano A, Stolovitzky G. 2014b. Toward better benchmarking: challenge-based methods assessment in cancer genomics. Genome Biol 15: 462.
12. Boutros PC, Fraser M, Harding NJ, de Borja R, Trudel D, Lalonde E, Meng A, Hennings-Yeomans PH, McPherson A, Sabelnykova VY, et al. 2015. Spatial genomic heterogeneity within localized, multifocal prostate cancer. Nat Genet 47: 736-745.
13. Buchhalter I, Hutter B, Alioto TS, Beck TA, Boutros PC, Brors B, Butler AP, Chotewutmontri S, Denroche RE, Derdak S, et al. 2014. A comprehensive multicenter comparison of whole genome sequencing pipelines using a uniform tumor-normal sample pair. bioRxiv doi: 10.1101/013177.
14. Canales RD, Luo Y, Willey JC, Austermiller B, Barbacioru CC, Boysen C, Hunkapiller K, Jensen RV, Knight CR, Lee KY, et al. 2006. Evaluation of DNA microarray results with quantitative gene expression platforms. Nat Biotechnol 24: 1115-1122.
15. The Cancer Genome Atlas Network. 2012a. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487: 330-337.
16. The Cancer Genome Atlas Network. 2012b. Comprehensive molecular portraits of human breast tumours. Nature 490: 61-70.
17. The Cancer Genome Atlas Network. 2015. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 517: 576-582.
18. The Cancer Genome Atlas Research Network. 2008. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061-1068.
19. Chong LC, Albuquerque MA, Harding NJ, Caloian C, Chan-Seng-Yue M, de Borja R, Fraser M, Denroche RE, Beck TA, van der Kwast T, et al. 2014. SeqControl: process control for DNA sequencing. Nat Methods 11: 1071-1075.
20. Cooper CS, Eeles R, Wedge DC, Van Loo P, Gundem G, Alexandrov LB, Kremeyer B, Butler A, Lynch AG, Camacho N, et al. 2015. Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. Nat Genet 47: 367-372.
21. Creixell P, Reimand J, Haider S, Wu G, Shibata T, Vazquez M, Mustonen V, Gonzalez-Perez A, Pearson J, Sander C, et al. 2015. Pathway and network analysis of cancer genomes. Nat Methods 12: 615-621.
22. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, et al. 2012. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486: 346-352.
23. Daley T, Smith AD. 2013. Predicting the molecular complexity of sequencing libraries. Nat Methods 10: 325-327.
24. de Bruin EC, McGranahan N, Mitter R, Salm M, Wedge DC, Yates L, Jamal- Hanjani M, Shafi S, Murugaesu N, Rowan AJ, et al. 2014. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science 346: 251-256.
25. Deshwar AG, Vembu S, Yung CK, Jang GH, Stein L, Morris Q. 2015. PhyloWGS: reconstructing subclonal composition and evolution from whole-genome sequencing of tumors. Genome Biol 16: 35.
26. Dvinge H, Git A, Graf S, Salmon-Divon M, Curtis C, Sottoriva A, Zhao Y, Hirst M, Armisen J, Miska EA, et al. 2013. The shaping and functional consequences of the microRNA landscape in breast cancer. Nature 497: 378-382.
27. Eirew P, Steif A, Khattra J, Ha G, Yap D, Farahani H, Gelmon K, Chia S, Mar C, Wan A, et al. 2015. Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution. Nature 518: 422-426.
28. Ewing AD, Houlahan KE, Hu Y, Ellrott K, Caloian C, Yamaguchi TN, Bare JC, P'ng C, Waggott D, Sabelnykova VY, et al. 2015. Combining tumor genome simulation with crowdsourcing to benchmark somatic single-nucleotide- variant detection. Nat Methods 12: 623-630.
29. Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, Chen H, Omeroglu G, Meterissian S, Omeroglu A, et al. 2008. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 14: 518-527.
30. Fox NS, Starmans MH, Haider S, Lambin P, Boutros PC. 2014. Ensemble analyses improve signatures of tumour hypoxia and reveal inter-platform differences. BMC Bioinformatics 15: 170.
31. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, et al. 2012. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366: 883-892.
32. Gerlinger M, Horswell S, Larkin J, Rowan AJ, Salm MP, Varela I, Fisher R, McGranahan N, Matthews N, Santos CR, et al. 2014. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat Genet 46: 225-233.
33. Gonzalez-Perez A, Mustonen V, Reva B, Ritchie GR, Creixell P, Karchin R, Vazquez M, Fink JL, Kassahn KS, Pearson JV, et al. 2013. Computational approaches to identify functional genetic variants in cancer genomes. Nat Methods 10: 723-729.
34. Govind SK, Zia A, Hennings-Yeomans PH, Watson JD, Fraser M, Anghel C, Wyatt AW, van der Kwast T, Collins CC, McPherson JD, et al. 2014. ShatterProof: operational detection and quantification of chromothripsis. BMC Bioinformatics 15: 78.
35. Gulati S, Martinez P, Joshi T, Birkbak NJ, Santos CR, Rowan AJ, Pickering L, Gore M, Larkin J, Szallasi Z, et al. 2014. Systematic evaluation of the prognostic impact and intratumour heterogeneity of clear cell renal cell carcinoma biomarkers. Eur Urol 66: 936-948.
36. Gundem G, Van Loo P, Kremeyer B, Alexandrov LB, Tubio JM, Papaemmanuil E, Brewer DS, Kallio HM, Hognas G, Annala M, et al. 2015. The evolutionary history of lethal metastatic prostate cancer. Nature 520: 353-357.
37. Ha G, Roth A, Khattra J, Ho J, Yap D, Prentice LM, Melnyk N, McPherson A, Bashashati A, Laks E, et al. 2014. TITAN: inference of copy number architectures in clonal cell populations from tumor whole-genome sequence data. Genome Res 24: 1881-1893.
38. Hanahan D, Weinberg RA. 2000. The hallmarks of cancer. Cell 100: 57-70.
39. Hanahan D, Weinberg RA. 2011. Hallmarks of cancer: the next generation. Cell 144: 646-674.
40. Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, Gupta S, Moore J, Wrobel MJ, Lerner J, et al. 2008. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 359: 1995-2004.
41. Hudson TJ, AndersonW, Artez A, Barker AD, Bell C, Bernabe RR, Bhan MK, Calvo F, Eerola I, Gerhard DS, et al. 2010. International network of cancer genome projects. Nature 464: 993-998.
42. Kratz JR, He J, Van Den Eeden SK, Zhu ZH, Gao W, Pham PT, Mulvihill MS, Ziaei F, Zhang H, Su B, et al. 2012. A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies. Lancet 379: 823-832.
43. Lalonde E, Ishkanian AS, Sykes J, Fraser M, Ross-Adams H, Erho N, Dunning MJ, Halim S, Lamb AD, Moon NC, et al. 2014. Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study. Lancet Oncol 15: 1521-1532.
44. Lapuk AV,Wu C, Wyatt AW, McPherson A, McConeghy BJ, Brahmbhatt S, Mo F, Zoubeidi A, Anderson S, Bell RH, et al. 2012. From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. J Pathol 227: 286-297.
45. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, Carter SL, Stewart C, Mermel CH, Roberts SA, et al. 2013. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499: 214-218.
46. Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR, Meyerson M, Gabriel SB, Lander ES, Getz G. 2014. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505: 495-501.
47. Leiserson MD, Vandin F, Wu HT, Dobson JR, Eldridge JV, Thomas JL, Papoutsaki A, Kim Y, Niu B, McLellan M, et al. 2015. Pan-cancer network analysis identifies combinations of rare somatic mutations across pathways and protein complexes. Nat Genet 47: 106-114.
48. Loeb S, Vonesh EF, Metter EJ, Carter HB, Gann PH, Catalona WJ. 2011. What is the true number needed to screen and treat to save a life with prostate-specific antigen testing? J Clin Oncol 29: 464-467.
49. Margolin AA, Bilal E, Huang E, Norman TC, Ottestad L, Mecham BH, Sauerwine B, Kellen MR, Mangravite LM, Furia MD, et al. 2013. Systematic analysis of challenge-driven improvements in molecular prognostic models for breast cancer. Sci Transl Med 5: 181re1.
50. Monzon FA, Lyons-Weiler M, Buturovic LJ, Rigl CT, Henner WD, Sciulli C, Dumur CI, Medeiros F, Anderson GG. 2009. Multicenter validation of a 1,550-gene expression profile for identification of tumor tissue of origin. J Clin Oncol 27: 2503-2508.
51. Navin N, Kendall J, Troge J, Andrews P, Rodgers L, McIndoo J, Cook K, Stepansky A, Levy D, Esposito D, et al. 2011. Tumour evolution inferred by single-cell sequencing. Nature 472: 90-94.
52. Oesper L, Satas G, Raphael BJ. 2014. Quantifying tumor heterogeneity in whole-genome and whole-exome sequencing data. Bioinformatics 30: 3532-3540.
53. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, LeeW, Yuan J, Wong P, Ho TS, et al. 2015. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348: 124-128.
54. Roth A, Khattra J, Yap D, Wan A, Laks E, Biele J, Ha G, Aparicio S, Bouchard- Cote A, Shah SP. 2014. PyClone: statistical inference of clonal population structure in cancer. Nat Methods 11: 396-398.
55. Shah SP, Morin RD, Khattra J, Prentice L, Pugh T, Burleigh A, Delaney A, Gelmon K, Guliany R, Senz J, et al. 2009. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 461: 809-813.
56. Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, Turashvili G, Ding J, Tse K, Haffari G, et al. 2012. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486: 395-399.
57. Shedden K, ChenW, Kuick R, Ghosh D, Macdonald J, Cho KR, Giordano TJ, Gruber SB, Fearon ER, Taylor JM, et al. 2005. Comparison of seven methods for producing Affymetrix expression scores based on false discovery rates in disease profiling data. BMC Bioinformatics 6: 26.
58. Shi L, Tong W, Fang H, Scherf U, Han J, Puri RK, Frueh FW, Goodsaid FM, Guo L, Su Z, et al. 2005. Cross-platform comparability of microarray technology: intra-platform consistency and appropriate data analysis procedures are essential. BMC Bioinformatics 6: pS12.
59. Shi L, Reid LH, Jones WD, Shippy R, Warrington JA, Baker SC, Collins PJ, de Longueville F, Kawasaki ES, Lee KY, et al. 2006. The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat Biotechnol 24: 1151-1161.
60. Shi L,Campbell G, Jones WD,Campagne F,WenZ, Walker SJ, Su Z, Chu TM, Goodsaid FM, Pusztai L, et al. 2010. The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol 28: 827-838.
61. Starmans MH, Fung G, Steck H, Wouters BG, Lambin P. 2011. A simple but highly effective approach to evaluate the prognostic performance of gene expression signatures. PLoS One 6: e28320.
62. Starmans MH, Pintilie M, John T, Der SD, Shepherd FA, Jurisica I, Lambin P, Tsao MS, Boutros PC. 2012. Exploiting the noise: improving biomarkers with ensembles of data analysis methodologies. Genome Med 4: 84.
63. Starmans MH, PintilieM, Chan-Seng-Yue M, Moon NC, Haider S, Nguyen F, Lau SK, Liu N, Kasprzyk A, Wouters BG, et al. 2015. Integrating RAS status into prognostic signatures for adenocarcinomas of the lung. Clin Cancer Res 21: 1477-1486.
64. Stephens PJ, Greenman CD, Fu B, Yang F, Bignell GR, Mudie LJ, Pleasance ED, Lau KW, Beare D, Stebbings LA, et al. 2011. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 144: 27-40.
65. Tofigh A, Suderman M, Paquet ER, Livingstone J, Bertos N, Saleh SM, Zhao H, Souleimanova M, Cory S, Lesurf R, et al. 2014. The prognostic ease and difficulty of invasive breast carcinoma. Cell Rep 9: 129-142.
66. Tran B, Brown AM, Bedard PL, Winquist E, Goss GD, Hotte SJ, Welch SA, Hirte HW, Zhang T, Stein LD, et al. 2013. Feasibility of real time next generation sequencing of cancer genes linked to drug response: results from a clinical trial. Int J Cancer 132: 1547-1555.
67. Van Allen EM, Wagle N, Stojanov P, Perrin DL, Cibulskis K, Marlow S, Jane- Valbuena J, Friedrich DC, Kryukov G, Carter SL, et al. 2014. Wholeexome sequencing and clinical interpretation of formalin-fixed, paraffin- embedded tumor samples to guide precision cancer medicine. Nat Med 20: 682-688.
68. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, et al. 2002. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530-536.
69. Vaske CJ, Benz SC, Sanborn JZ, Earl D, Szeto C, Zhu J, Haussler D, Stuart JM. 2010. Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM. Bioinformatics 26: i237-i245.
70. Venet D, Dumont JE, Detours V. 2011. Most random gene expression signatures are significantly associated with breast cancer outcome. PLoS Comput Biol 7: e1002240.
71. Vollan HK, Rueda OM, Chin SF, Curtis C, Turashvili G, Shah S, Lingjaerde OC, Yuan Y, Ng CK, Dunning MJ, et al. 2015. A tumor DNA complex aberration index is an independent predictor of survival in breast and ovarian cancer. Mol Oncol 9: 115-127.
72. Wang Y, Waters J, Leung ML, Unruh A, Roh W, Shi X, Chen K, Scheet P, Vattathil S, Liang H, et al. 2014. Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature 512: 155-160.
73. Wu G, Feng X, Stein L. 2010. A human functional protein interaction network and its application to cancer data analysis. Genome Biol 11: R53.
74. Yang L, Luquette LJ, Gehlenborg N, Xi R, Haseley PS, Hsieh CH, Zhang C, Ren X, Protopopov A, Chin L, et al. 2013. Diverse mechanisms of somatic structural variations in human cancer genomes. Cell 153: 919-929.
75. Yuan Y, Failmezger H, Rueda OM, Ali HR, Graf S, Chin SF, Schwarz RF, Curtis C, Dunning MJ, Bardwell H, et al. 2012. Quantitative image analysis of cellular heterogeneity in breast tumors complements genomic profiling. Sci Transl Med 4: 157ra143.
76. Yuan Y, Van Allen EM, Omberg L, Wagle N, Amin-Mansour A, Sokolov A, Byers LA, Xu Y, Hess KR, Diao L, et al. 2014. Assessing the clinical utility of cancer genomic and proteomic data across tumor types. Nat Biotechnol 32: 644-652.
77. Zack TI, Schumacher SE, Carter SL, Cherniack AD, Saksena G, Tabak B, Lawrence MS, Zhang CZ, Wala J, Mermel CH, et al. 2013. Pan-cancer patterns of somatic copy number alteration. Nat Genet 45: 1134-1140.
78. Zhang J, Fujimoto J, Wedge DC, Song X, Seth S, ChowCW, Cao Y, Gumbs C, Gold KA, Kalhor N, et al. 2014. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science 346: 256-259.
79. Zhu Q, Miecznikowski JC, Halfon MS. 2010. Preferred analysis methods for Affymetrix GeneChips. II. An expanded, balanced, wholly-defined spike-in dataset. BMC Bioinformatics 11: 285.